Eledon Posts Q3 Loss, $69.7M Cash Into Q2 2027, Phase 3 LEGACY Set for Q4
ELDN sits 79% above its 52-week low of $1.35.
Summary
Eledon reported a Q3 2026 net loss of $3.9M (a $21.0M loss excluding a $17.0M non-cash warrant gain) and $69.7M in cash that funds operations into Q2 2027, while the Phase 3 LEGACY kidney trial stays on track to start in Q4 2026.
Key Events · Earnings and Guidance · ELDN
-
Q3 2026 Results Reported
Net loss of $3.9M, or $0.03 per share, versus $17.5M ($0.21) in Q3 2025; R&D rose to $17.8M from $15.0M.
-
Warrant Gain Masks Operating Loss
The quarter included a non-cash $17.0M gain from change in fair value of warrant liabilities; excluding it, net loss would have been $21.0M.
-
Cash Runway Into Q2 2027
Cash, cash equivalents and short-term investments totaled $69.7M at September 30, 2026, down from $133.3M at December 31, 2025.
-
Phase 3 LEGACY On Track for Q4
Global Phase 3 kidney transplant trial expected to enroll ~600 patients with a 52-week non-inferiority endpoint versus tacrolimus.
Analysis · ELDN · Life Sciences
Runway and trial timing dominate Eledon's Q3 update. With $69.7M in cash funding operations only into Q2 2027, a financing is likely needed before the Phase 3 LEGACY kidney trial — roughly 600 patients starting in Q4 2026 — gets far. The reported $3.9M net loss is flattered by a $17.0M non-cash gain from warrant remeasurement; excluding it, the loss was $21.0M, and R&D spending rose to $17.8M from $15.0M a year ago. On the positive side, FDA Fast Track for kidney transplant and a cleared IND for an islet cell registrational study broaden the tegoprubart program.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELDN was trading at $2.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.2M. The 52-week trading range was $1.35 to $4.49. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.